Nabi Biopharmaceuticals is divesting its Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals for $185 million.
Biotest will thus acquire the Biologics SBU’s products including Nabi-HB®, a marketed therapy indicated to prevent hepatitis B infection. It will also gain all the plasma business assets such as the plasma protein production plant and nine FDA-certified plasma collection centers across the U.S.
“With the acquisition of Nabi Biologics, we have found the ideal complement for our European plasma protein business and have become a global player in the industry,” comments Gregor Schulz, chairman of the management board of Biotest.
After the closing of the transaction, Nabi Biopharmaceuticals will operate its Pharmaceuticals SBU from its existing Rockville, MD facility, which will become its new headquarters.